Tirzepatide Once Weekly for the Treatment of Obesity.

Studied

Phase 3 randomized trial comparing three studied tirzepatide doses with placebo for weight loss.

Who / model

2539 adults with obesity, or overweight with a weight-related complication, without diabetes; treatment lasted 72 weeks.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Both main weight outcomes favored tirzepatide. Across increasing studied doses, average weight fell 15.0%, 19.5% and 20.9%, versus 3.1% with placebo. At least 5% weight loss occurred in 85%, 89% and 91%, versus 35%. Digestive symptoms were common; adverse events caused treatment withdrawal in 4.3%, 7.1% and 6.2%, versus 2.6%.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary